Increased omeprazole metabolism in carriers of the <i>CYP2C19*17</i> allele; a pharmacokinetic study in healthy volunteers

Abstract

The pharmacokinetics of omeprazole and omeprazole sulphone differ significantly between homozygous CYP2C19*17 and CYP2C19*1 subjects. For clinically important drugs that are metabolized predominantly by CYP2C19, the CYP2C19*17 allele might be associated with subtherapeutic drug exposure.